Major trial tests new mpox vaccine for vulnerable groups
NCT ID NCT06223919
Summary
This large study is testing whether the LC16m8 vaccine is safe and effective at preventing mpox infection. It involves 8,686 adults in Colombia who are at high risk for mpox, including men who have sex with men and people living with HIV. Participants are randomly assigned to receive the vaccine immediately or after a 6-week delay to compare infection rates over 180 days.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONKEYPOX are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinica Universitaria Colombia - Centro Medico Teusaquillo
Bogotá, Bogota D.C., Colombia
-
Hospital Universitario San Ignacio
Bogotá, Bogota D.C., Colombia
-
Infecto Clinicos
Bogotá, Bogota D.C., Colombia
Conditions
Explore the condition pages connected to this study.